Pathophysiology of increased urinary N-acetyl-beta-D-glucosaminidase activity in human hypertension: effect of cilazapril therapy.

To investigate the pathophysiology of elevated urinary N-acetyl-beta-D-glucosaminidase (NAG) activity in human hypertension, total and fractional urinary NAG activities were correlated with Li clearance, a measure of proximal renal tubular Na reabsorption, in 15 white hypertensive subjects, aged 56 years, and in 13 normotensive control subjects. In 11 hypertensive subjects, the measurements were repeated after 2 months of antihypertensive therapy with the converting enzyme inhibitor cilazapril (2.5 or 5.0 mg daily). Urinary NAG activity was increased in hypertensives and correlated directly with Li clearance in both hypertensive and normotensive subjects. Li clearance and urinary NAG activity were reduced by antihypertensive therapy. The findings indicate an inverse correlation between urinary NAG activity and proximal renal tubular Na reabsorption, suggesting that NAG is reabsorbed in the proximal renal tubules with Na and other proteins. High Li clearance and urinary NAG activity in hypertension are in part functional and, therefore, reversible disturbances of renal function.

[1]  L. Ruilope,et al.  Multiple effects of calcium entry blockers on renal function in hypertension. , 1987, Hypertension.

[2]  J. Bauer,et al.  Renal effects of angiotensin converting enzyme inhibitors in hypertension. , 1986, The American journal of medicine.

[3]  A. Weder Red-cell lithium-sodium countertransport and renal lithium clearance in hypertension. , 1986, The New England journal of medicine.

[4]  H. Langford,et al.  Differential effect of salt loading on sodium and lithium excretion in Dahl salt-resistant and -sensitive rats. , 1984, Hypertension.

[5]  S. Morioka,et al.  Increased serum and urinary N-acetyl-beta-D-glucosaminidase activity in human hypertension: early indicator of renal dysfunction. , 1984, Clinical and experimental hypertension. Part A, Theory and practice.

[6]  D. Drayer,et al.  Increased excretion of urinary N-acetyl-beta-glucosaminidase in essential hypertension and its decline with antihypertensive therapy. , 1983, The New England journal of medicine.

[7]  B. Leyland-Jones,et al.  N-acetyl-beta-glucosaminidase and beta 2-microglobulin. Their urinary excretion in patients with renal parenchymal disease. , 1983, Archives of internal medicine.

[8]  G. Simon,et al.  Increased SERUM N-Acetyl-β-D-Glucosaminidase Activity in Human Hypertension , 1982 .

[9]  R. B. Goudie,et al.  Unstable mutation in vitiligo. , 1980, Lancet.

[10]  N. Jones,et al.  Detection of renal artery stenosis by measuring urinary N-acetyl-beta-D-glucosaminidase. , 1978, British medical journal.

[11]  A. Fredriksson Renal handling of beta2-microglobulin in experimental renal disease. , 1975, Scandinavian journal of clinical and laboratory investigation.

[12]  W. Raab Diagnostic value of urinary enzyme determinations. , 1972, Clinical chemistry.